US obesity is edging down as GLP-1 prescriptions climb, but high prices and low coverage may limit impact.

Ad watchdog sides with pharma over misleading GLP-1 microdose telehealth marketing—but this scrutiny won't impact sales thanks to high consumer demand.

Its roughly 30% average weight loss could expand options and accelerate a tiered treatment market ranging from oral pill convenience to surgical intervention for those with severe obesity.

Telehealth firms switching from compounded to brand-name GLP-1s must offer stronger patient support and expand into other high-demand treatments, like hormone therapies.

Novo beat Q1 expectations thanks to Wegovy pill buzz as Lilly readies rival Foundayo, setting up weight loss drugs’ next ad showdown.

The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.

It generated nearly $20 billion sales in Q1, led by GLP-1 brands Mounjaro and Zepbound, positioning it ahead of a pill rivalry with Novo.

With insurers declining to participate in GLP-1 coverage, Medicare will now subsidize the drugs, though concerns around muscle loss may temper prescribing.

The $625 million raise signals Wall Street’s conviction in durable GLP-1 weight loss drug demand even as more players crowd the field.

Drug brands invested $1.6B in linear, down 8% QoQ, while NFL and Olympics broadcasts dominated total spending.

As Medicare GLP-1 coverage begins, Walmart can capture more weight-care demand from its boomer customer base.

A new partnership between Novo Nordisk and OpenAI underscores pharma’s urgency to harness AI for quicker cures.

Rapid share gains in India come at the expense of branded drugs, challenging premium pricing models and raising the bar for new entrants.

Pharmacies and telehealth brands are racing to capture GLP-1 pill users, making strong customer service and patient support essential.

The stage is set for a market share battle over efficacy, convenience, and brand recognition.

Its exclusive Insilico licensing reflects pharma’s move to AI-driven early discovery to speed development and trim costs.

Novo is testing tiered subscriptions to boost Wegovy adherence—but whether patients stay on their meds will hinge on post-prescription support from its telehealth partners.

The move signals a consumer marketing strategy shift as GLP-1 drugs demand loyalty, engagement, and experience beyond clinical outcomes.

Its next generation GLP-1 achieved breakout weight loss results that extend its lead in the obesity market, but reopen questions about excessive weight loss.

Structure Therapeutics' pill matches Novo’s and Lilly’s on weight loss, teeing up fiercer competition.